Edition:
United States

Profile: Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

116.90EUR
11:35am EDT
Change (% chg)

€-1.00 (-0.85%)
Prev Close
€117.90
Open
€119.50
Day's High
€121.40
Day's Low
€116.90
Volume
134,365
Avg. Vol
123,754
52-wk High
€155.95
52-wk Low
€98.85

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Company Address

Ipsen SA

65, quai Georges Gorse
BOULOGNE-BILLANCOURT     92100
P: +331.58335000
F: +331.58335001

Company Web Links